A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F18%3A10382641" target="_blank" >RIV/00216208:11150/18:10382641 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/18:10382641
Result on the web
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29755669" target="_blank" >https://www.ncbi.nlm.nih.gov/pubmed/29755669</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.18632/oncotarget.24980" target="_blank" >10.18632/oncotarget.24980</a>
Alternative languages
Result language
angličtina
Original language name
A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer
Original language description
Biomarker analysis has become routine practice in the treatment of non-small cell lung cancer (NSCLC). To ensure high quality testing, participation to external quality assessment (EQA) schemes is essential. This article provides a longitudinal overview of the EQA performance for EGFR, ALK, and ROS1 analyses in NSCLC between 2012 and 2015. The four scheme years were organized by the European Society of Pathology according to the ISO 17043 standard. Participants were asked to analyze the provided tissue using their routine procedures. Analysis scores improved for individual laboratories upon participation to more EQA schemes, except for ROS1 immunohistochemistry (IHC). For EGFR analysis, scheme error rates were 18.8%, 14.1% and 7.5% in 2013, 2014 and 2015 respectively. For ALK testing, error rates decreased between 2012 and 2015 by 5.2%, 3.2% and 11.8% for the fluorescence in situ hybridization (FISH), FISH digital, and IHC subschemes, respectively. In contrast, for ROS1 error rates increased between 2014 and 2015 for FISH and IHC by 3.2% and 9.3%. Technical failures decreased over the years for all three markers. Results show that EQA contributes to an ameliorated performance for most predictive biomarkers in NSCLC. Room for improvement is still present, especially for ROS1 analysis.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30109 - Pathology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Oncotarget
ISSN
1949-2553
e-ISSN
—
Volume of the periodical
9
Issue of the periodical within the volume
29
Country of publishing house
US - UNITED STATES
Number of pages
15
Pages from-to
20524-20538
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-85045521709